Broncho-munal® + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Uncomplicated Respiratory Tract Infections
Conditions
Acute Uncomplicated Respiratory Tract Infections
Trial Timeline
Nov 7, 2022 → Dec 18, 2022
NCT ID
NCT05588804About Broncho-munal® + Placebo
Broncho-munal® + Placebo is a phase 3 stage product being developed by Sandoz Group for Acute Uncomplicated Respiratory Tract Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT05588804. Target conditions include Acute Uncomplicated Respiratory Tract Infections.
What happened to similar drugs?
20 of 20 similar drugs in Acute Uncomplicated Respiratory Tract Infections were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05588804 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Uncomplicated Respiratory Tract Infections